Skip to main content

Diaphragm Abnormalities in Patients with End-Stage Heart Failure: NADPH Oxidase Upregulation and Protein Oxidation.

Publication ,  Journal Article
Ahn, B; Coblentz, PD; Beharry, AW; Patel, N; Judge, AR; Moylan, JS; Hoopes, CW; Bonnell, MR; Ferreira, LF
Published in: Front Physiol
2016

Patients with heart failure (HF) have diaphragm abnormalities that contribute to disease morbidity and mortality. Studies in animals suggest that reactive oxygen species (ROS) cause diaphragm abnormalities in HF. However, the effects of HF on ROS sources, antioxidant enzymes, and protein oxidation in the diaphragm of humans is unknown. NAD(P)H oxidase, especially the Nox2 isoform, is an important source of ROS in the diaphragm. Our main hypothesis was that diaphragm from patients with HF have heightened Nox2 expression and p47phox phosphorylation (marker of enzyme activation) that is associated with elevated protein oxidation. We collected diaphragm biopsies from patients with HF and brain-dead organ donors (controls). Diaphragm mRNA levels of Nox2 subunits were increased 2.5-4.6-fold over controls (p < 0.05). Patients also had increased protein levels of Nox2 subunits (p47phox, p22phox, and p67phox) and total p47phox phosphorylation, while phospho-to-total p47phox levels were unchanged. The antioxidant enzyme catalase was increased in patients, whereas glutathione peroxidase and superoxide dismutases were unchanged. Among markers of protein oxidation, carbonyls were increased by ~40% (p < 0.05) and 4-hydroxynonenal and 3-nitrotyrosines were unchanged in patients with HF. Overall, our findings suggest that Nox2 is an important source of ROS in the diaphragm of patients with HF and increases in levels of antioxidant enzymes are not sufficient to maintain normal redox homeostasis. The net outcome is elevated diaphragm protein oxidation that has been shown to cause weakness in animals.

Duke Scholars

Published In

Front Physiol

DOI

ISSN

1664-042X

Publication Date

2016

Volume

7

Start / End Page

686

Location

Switzerland

Related Subject Headings

  • 3208 Medical physiology
  • 3101 Biochemistry and cell biology
  • 1701 Psychology
  • 1116 Medical Physiology
  • 0606 Physiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahn, B., Coblentz, P. D., Beharry, A. W., Patel, N., Judge, A. R., Moylan, J. S., … Ferreira, L. F. (2016). Diaphragm Abnormalities in Patients with End-Stage Heart Failure: NADPH Oxidase Upregulation and Protein Oxidation. Front Physiol, 7, 686. https://doi.org/10.3389/fphys.2016.00686
Ahn, Bumsoo, Philip D. Coblentz, Adam W. Beharry, Nikhil Patel, Andrew R. Judge, Jennifer S. Moylan, Charles W. Hoopes, Mark R. Bonnell, and Leonardo F. Ferreira. “Diaphragm Abnormalities in Patients with End-Stage Heart Failure: NADPH Oxidase Upregulation and Protein Oxidation.Front Physiol 7 (2016): 686. https://doi.org/10.3389/fphys.2016.00686.
Ahn B, Coblentz PD, Beharry AW, Patel N, Judge AR, Moylan JS, et al. Diaphragm Abnormalities in Patients with End-Stage Heart Failure: NADPH Oxidase Upregulation and Protein Oxidation. Front Physiol. 2016;7:686.
Ahn, Bumsoo, et al. “Diaphragm Abnormalities in Patients with End-Stage Heart Failure: NADPH Oxidase Upregulation and Protein Oxidation.Front Physiol, vol. 7, 2016, p. 686. Pubmed, doi:10.3389/fphys.2016.00686.
Ahn B, Coblentz PD, Beharry AW, Patel N, Judge AR, Moylan JS, Hoopes CW, Bonnell MR, Ferreira LF. Diaphragm Abnormalities in Patients with End-Stage Heart Failure: NADPH Oxidase Upregulation and Protein Oxidation. Front Physiol. 2016;7:686.

Published In

Front Physiol

DOI

ISSN

1664-042X

Publication Date

2016

Volume

7

Start / End Page

686

Location

Switzerland

Related Subject Headings

  • 3208 Medical physiology
  • 3101 Biochemistry and cell biology
  • 1701 Psychology
  • 1116 Medical Physiology
  • 0606 Physiology